Brief: Oncopeptides Says CHMP Issues A Positive Opinion Recommending Full Approval Of Oncopeptides Pepaxti In EU For Patients With Triple Class Refractory Multiple Myeloma
23/06/2022 16:57
June 23 (Reuters) - Oncopeptides AB ONCO.ST :
* CHMP ISSUES A POSITIVE OPINION RECOMMENDING FULL APPROVAL
OF
ONCOPEPTIDES PEPAXTI IN EU FOR PATIENTS WITH TRIPLE CLASS
REFRACTORY MULTIPLE MYELOMA
Source text for Eikon: ID:nWkrbMrM5m
Further company coverage: ONCO.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oncopeptides AB
See all newsSweden's Oncopeptides Q3 net sales rise on Pepaxti demand
Brief: Oncopeptides Q3 Operating Profit SEK -36.47 Million
Brief: Oncopeptides Completes Directed Share Issue Of SEK 100 Mln
Brief: Oncopeptides Confirms Blood-Brain-Barrier Penetration In Glioblastoma Study
Swedish biotech Oncopeptides' Q2 net sales rise on strong demand in Italy